Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MDG1015 in Advanced NY-ESO-1/LAGE-1a Positive Solid Tumors
NCT06748872Phase 1Not yet recruiting
- Sponsor
- Medigene AG
- Start
- Jul 2025
- Primary completion
- Dec 2027
- Modality
- TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MDG1015 in epithelial ovarian cancer (EOC), gastroesophageal junction adenocarcinoma, myxoid liposarcoma (MLPS) and 1 more, sponsored by Medigene AG. Primary endpoints: Adverse Events and Dose Limiting Toxicities at 28 days and Adverse Events at 12 months. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
MDG1015
03
Conditions
epithelial ovarian cancer (EOC)gastroesophageal junction adenocarcinomamyxoid liposarcoma (MLPS)synovial sarcoma (SS)
Beyond the preview
Go deeper on NCT06748872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06748872.